Trial Profile
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb14045 in Patients With CD123-Expressing Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Vibecotamab (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Haematological malignancies; Hypereosinophilic syndrome; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors Xencor
- 04 Mar 2022 Status changed from recruiting to completed.
- 04 Aug 2021 Planned End Date changed from 1 Feb 2021 to 1 Feb 2023.
- 04 Aug 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2022.